Effects of t-AMCHA and EACA on the Plasma Kallikrein System

Summary

Varied amounts of t-AMCHA or EACA added to non-contact fresh dog plasma generates kininogenase and TAME esterase activities. These phenomena may be abolished by prior addition of lima bean trypsin inhibitor. t-AMCHA or EACA had no effect on partially purified kallikrein, but had a significant inhibitory influence on plasma kininase. The generation of prekallikrein activator with t-AMCHA was ascertained by gel filtration on a Sephadex G-100 column. The blood kinin level increased about 50% one hr after administration of t-AMCHA. It is suggested from these results that t-AMCHA may initiate the true activation of the kallikrein system by activating the Hageman factor.

• References

• 1 Abe E, Watanabe N, Kumagai T, Mouri T, Seki T. Estimation of kinin in peripheral blood in man. Tohoku Journal of experimental Medicine 1966; 89: 103
• 2 Armstrong G, Stewart J.W. Formation of plasma kinin in human plasma by ɛ-amino ca-proic acid and certain related compounds. Journal of Physiology 1960; 154: 19P
• 3 Briseid K, Dyrud O.K, Öie S. Determination of factors of the kinin system in rat plasma. Acta Pharmacologica et Toxicologica 1970; 28: 124
• 4 Cochrane C.G, Wuepper K.D. The first component of the kinin-forming system in human and rabbit plasma. Journal of experimental Medicine 1971; 134.: 986
• 5 Colman R.W, Mattler L, Sherry S. Studies on the prekallikrein (kallikreinogen)-kalli-krein enzyme system of human plasma. II. Evidence relating the kaolin-activated arginine esterase to plasma kallikrein. The Journal of Clinical Investigation 1969; 48: 23
• 6 Eisen V, Glanville K.L.A. Separation of kinin-forming factors in human plasma. British Journal of experimental Pathology 1969; 50: 38
• 7 Erdös E.G, Sloane E.M. An enzyme in human blood plasma that inactivates bradykinin and kallidins. Biochemical Pharmacology 1962; 11: 585
• 8 Erdös E.G, Renfrew A.G, Slone E.M, Wohler J.R. Enzymatic studies on bradykinin and similar peptides. Annals of the New York Academy of Sciences 1963; 104: 222
• 9 Gjønnaess H. Cold promoted activation of factor VII, IV. Relation to the coagulation system. Thrombosis et Diathesis Haemorrhagica 1972; 28: 194
• 10 Herbert R.J, Ogston D, Douglas A. Further purification and properties of Hageman factor cofactor. Biochimica Biophysica Acta 1972; 271: 371
• 11 Iatridis S.G, Ferguson J.H. Active Hageman factor: a plasma lysokinase of the human fibrinolytic system. The Journal of Clinical Investigation 1962; 41: 1277
• 12 Jensen K.B, Vennerød A.M. Purification of the main kinin of human urine. Acta Pharmacologica 1962; 19: 265
• 13 Kaplan A.P, Austen K.F. A pre-albumin activator of prekallikrein. Journal of Immunology 1970; 105: 802
• 14 Kaplan A.P, Austen K.F. A pre-albumin activator of prekallikrein II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. Journal of experimental Medicine 1971; 134: 696
• 15 Margolis J. Activation of plasma by contact with glass: evidence for common reaction which releases plasma kinin and initiate coagulation. Journal of Physiology (Lond.) 1958; 144: 1
• 16 Movat H.Z, Dilorenzo N.L. Activation of the plasma kinin system by antigen-antibody aggregates. I. Generation of permeability factor in guinea pig serum. Laboratory Investigation 1968; 19: 187
• 17 Movat H.A, Doon N.C, Takeuchi Y. The kinin-system of human plasma. I. Isolation of a low molecular weight activator of prekallikrein. International Archives of Allergy 1971; 40: 89
• 18 Nagasawa S, Takahashi H, Koida M, Susuki T, Schoenmakers J.G. Partial purification of bovine plasma kallikreinogen, its activation by the Hageman factor. Biochemical and Biophysical Research Communications 1968; 32: 644
• 19 Nakahara M, Tokita T. Capillary permeability effects of synovial fluiel, AMCHA. EACA and prednisolone acetate. Nature, no 1967; 5114: 497
• 20 Nakahara M. The effect of a tourniquet on the kinin-kininogen system in blood and muscle. Thrombosis et Diathesis Haemorrhagica 1971; 26: 264
• 21 Nakahara M. Plasma hippuryl-L-lysine hydrolase inhibition by low molecular weight substance in lysosomes of skeletal muscle. Biochemical Pharmacology 1972; 21: 2635
• 22 Nakahara M. Activation of dog plasma kallikrein with glass and acetone. Biochemical Pharmacology 1976; 25: 631
• 23 Nilsson I, Björkman S.E, Andersson L. Clinical experiences with ɛ-aminocaproic acid (ɛ-ACA) as an antifibrinolytic agent. Acta Medica Scandinavica 1961; 170: 487
• 24 Ogston D, Ogston C.M, Ratnoff O.A, Forbes C.D. Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: the participitation of Hageman factor and additional cofactors. The Journal of Clinical Investigation 1969; 48: 1786
• 25 Okamoto S, Oshiba S, Mihara H, Okamoto U. Synthetic inhibitors of fibrinolysis in vitro and in vivo mode of action. Annals of the New York Academy of Sciences 1968; 146: 414
• 26 Ratnoff O.D, Davie E.W, Mallet D.L. Studies on the action of Hageman factor. Evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent. The Journal of Clinical Investigation 1961; 40: 803
• 27 Rinvik S.F, Dyrud O.K, Briseid K. Determination of plasma kininogen, plasma kininase and erythrocyte kininase. Acta pharmacologica et Toxicologica 1966; 24: 169
• 28 Schoenmakers J.G.G, Matze R, Haanen C, Zilliken F. Hageman factor, a novel sialoglycoprotein with esterase activity. Biochimica et Biophysica Acta 1965; 101: 166
• 29 Stormorken H. Relation of the fibrinolytic to other biological systems. Thrombosis et Diathesis Haemorrhagica 1975; 34: 378
• 30 Storti E, Traldi A, Tosatti E, Davoli P.G. Synovectomy for haemophilic haemoar-throsis. Lancet, II 1968; 572
• 31 Vennerød A.M, Laake K. Isolation and characterization of a prealbumin activator of prekallikrein from acetone-activated human plasma. Thrombosis Research 1974; 4: 103